News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
An Iowa State University study concluded that Immunocidin Equine was effective in 52.9% of the cases enrolled (that had a known outcome) after 2-5 injections. The treatment was deemed safe, with swelling the only side effect.
Data from a study with Settle® has been published in the Journal of Equine Veterinary Science. The data show a positive effect of Settle on postpartum uterine involution in the mare, particularly with a two-dose regimen.
Data from a University of Kentucky study assessing the effect of Settle on histological involution, cell-mediated immunity of the uterus, and clinical endpoints associated with involution was presented in Germany today.
NovaVive's Immunocidin® Equine anticancer immunotherapeutic for horses will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in sarcoids and squamous cell carcinoma.
NovaVive's immunotherapeutic for the treatment of equine endometritis, Settle®, has been approved for sale to New Zealand veterinarians by the NZ regulator. It was previously approved for sale in the U.S. and Australia.
An equine-specific version of Immunocidin® for equine sarcoid tumors is now available to Canadian veterinarians. The new product, Immunocidin® Equine, is packaged in 5mL vials and is approved by the Canadian regulator (CFIA).